API | epiceram

epiceram Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

EpiCeram is a topical non-steroidal skin cream. Based on the research of Peter M. Elias, it is made up of ceramides, free fatty acids, and cholesterol, and is designed to treat atopic dermatitis, a type of eczema. Ceragenix obtained marketing clearance from the U.S. Food and Drug Administration in April 2006. This prescription medical device works as a moisturizer and barrier cream. In the US, it requires prescription and was launched in October 2008 by Promius Pharma. EpiCeram was acquired by PuraCap Pharmaceutical LLC in 2010. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

epiceram

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Skin Diseases

Experimental Indications - Clinical Trial Phases 1-4 (4)

Asthma (Phase 3)

Dermatitis, Atopic (Phase 4)

Eczema (Phase 3)

Food Hypersensitivity (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue